RXRX
Recursion Pharmaceuticals, Inc. NASDAQ Listed Apr 16, 2021$3.27
Mkt Cap $1.5B
52w Low $2.80
10.8% of range
52w High $7.18
50d MA $3.41
200d MA $4.49
P/E (TTM)
-2.4x
EV/EBITDA
-2.1x
P/B
1.3x
Debt/Equity
0.1x
ROE
-57.0%
P/FCF
-4.8x
RSI (14)
—
ATR (14)
—
Beta
1.01
50d MA
$3.41
200d MA
$4.49
Avg Volume
16.1M
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
41 South Rio Grande Street · Salt Lake City, UT 84101 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | BMO | -0.28 | -0.21 | +25.0% | 3.77 | -2.4% | +0.0% | -2.7% | -1.1% | -2.5% | +2.8% | — |
| Nov 5, 2025 | BMO | -0.38 | -0.36 | +5.3% | 4.96 | +0.4% | -6.9% | +0.0% | -2.4% | +4.4% | -1.3% | — |
| Aug 5, 2025 | BMO | -0.35 | -0.41 | -17.1% | 5.53 | -2.0% | -0.9% | -1.3% | -0.9% | -1.3% | +2.3% | — |
| May 5, 2025 | BMO | -0.44 | -0.50 | -13.6% | 4.76 | -2.1% | -12.6% | +0.7% | +4.8% | -1.4% | +7.2% | — |
| Feb 28, 2025 | BMO | -0.44 | -0.53 | -20.5% | 7.51 | +4.8% | -12.3% | -1.8% | +1.7% | -5.2% | +5.6% | — |
| Nov 6, 2024 | BMO | -0.33 | -0.34 | -3.0% | 6.97 | -0.7% | -0.6% | +2.5% | +10.4% | -3.3% | -3.4% | — |
| Aug 8, 2024 | BMO | -0.35 | -0.40 | -14.3% | 6.64 | +2.9% | -5.3% | -4.1% | +8.5% | -4.0% | +6.5% | — |
| May 9, 2024 | BMO | -0.43 | -0.39 | +9.3% | 8.64 | +4.7% | -0.5% | +10.2% | +6.0% | -0.4% | -5.0% | — |
| Feb 27, 2024 | BMO | -0.46 | -0.40 | +13.0% | 15.52 | -10.8% | -16.6% | +4.0% | -4.8% | -4.0% | -3.2% | — |
| Nov 9, 2023 | BMO | -0.38 | -0.43 | -13.2% | 5.23 | +1.1% | +4.4% | +6.8% | +10.8% | +11.1% | -7.1% | — |
| Aug 8, 2023 | BMO | -0.38 | -0.38 | +0.0% | 11.55 | +0.4% | -5.0% | -9.0% | -4.1% | -2.6% | -1.4% | — |
| May 8, 2023 | BMO | -0.34 | -0.34 | +0.0% | 5.60 | -1.1% | +2.9% | -4.3% | -2.0% | -2.0% | +5.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | JP Morgan | Maintains | Overweight → Overweight | — | $3.30 | $3.33 | +0.9% | +4.8% | -2.0% | +3.8% | -4.3% | +1.8% |
| Feb 26 | BofA Securities | Maintains | Neutral → Neutral | — | $3.77 | $3.68 | -2.4% | +0.0% | -2.7% | -1.1% | -2.5% | +2.8% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $3.77 | $3.68 | -2.4% | +0.0% | -2.7% | -1.1% | -2.5% | +2.8% |
| Dec 17 | JP Morgan | Upgrade | Neutral → Overweight | — | $4.20 | $4.51 | +7.4% | +11.4% | -5.1% | -4.1% | +3.3% | -0.9% |
| Sep 11 | Needham | Maintains | Buy → Buy | — | $4.54 | $4.56 | +0.4% | +6.8% | -0.4% | -1.2% | +1.5% | -2.7% |
| Jul 8 | Needham | Maintains | Buy → Buy | — | $4.93 | $5.01 | +1.6% | +8.7% | +4.3% | +2.3% | -7.7% | +0.0% |
| Jun 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.92 | $5.01 | +1.8% | +1.6% | -3.2% | +5.6% | -1.6% | -4.0% |
| May 6 | Needham | Maintains | Buy → Buy | — | $4.76 | $4.66 | -2.1% | -12.6% | +0.7% | +4.8% | -1.4% | +7.2% |
| Apr 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.65 | $4.60 | -1.1% | -3.0% | +27.7% | -4.3% | +2.4% | -5.7% |
| Apr 8 | Needham | Maintains | Buy → Buy | — | $4.20 | $4.49 | +6.9% | -5.5% | +17.1% | -3.0% | +27.7% | -4.3% |
| Feb 28 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $7.67 | $6.71 | -12.5% | -2.1% | -12.3% | -1.8% | +1.7% | -5.2% |
| Feb 6 | Needham | Maintains | Buy → Buy | — | $7.92 | $8.14 | +2.8% | -8.6% | +3.5% | +2.1% | +0.1% | +8.9% |
| Jan 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $7.49 | $7.31 | -2.4% | -3.1% | -5.2% | -2.0% | -6.2% | +1.6% |
| Dec 11 | Needham | Maintains | Buy → Buy | — | $7.46 | $7.89 | +5.8% | +1.5% | -7.8% | -0.4% | +7.1% | -4.3% |
| Nov 20 | Needham | Maintains | Buy → Buy | — | $6.27 | $6.30 | +0.5% | -3.7% | -4.8% | -0.9% | +5.3% | -1.8% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $6.97 | $6.92 | -0.7% | -0.6% | +2.5% | +10.4% | -3.3% | -3.4% |
| Sep 4 | Needham | Maintains | Buy → Buy | — | $6.07 | $6.05 | -0.3% | +0.5% | +1.1% | -4.1% | +3.4% | +3.3% |
| Sep 3 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $7.28 | $6.46 | -11.3% | -16.6% | +0.5% | +1.1% | -4.1% | +3.4% |
| Sep 3 | Jefferies | Maintains | Hold → Hold | — | $7.28 | $6.46 | -11.3% | -16.6% | +0.5% | +1.1% | -4.1% | +3.4% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $6.64 | $6.83 | +2.9% | -5.3% | -4.1% | +8.5% | -4.0% | +6.5% |
| Jul 11 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $7.23 | $7.44 | +2.9% | +6.2% | +8.9% | -1.9% | +4.9% | -2.9% |
| Jun 25 | Needham | Maintains | Buy → Buy | — | $9.34 | $9.45 | +1.2% | +0.4% | -6.6% | -13.5% | -1.1% | -0.5% |
| May 10 | Needham | Maintains | Buy → Buy | — | $8.64 | $9.05 | +4.7% | -0.5% | +10.2% | +6.0% | -0.4% | -5.0% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $9.00 | $9.00 | +0.0% | +1.0% | -5.6% | +4.0% | -5.7% | -7.4% |
| Mar 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $12.81 | $12.92 | +0.9% | -4.0% | -3.2% | -5.0% | -1.5% | +0.4% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $15.52 | $13.84 | -10.8% | -16.6% | +4.0% | -4.8% | -4.0% | -3.2% |
| Jan 17 | Needham | Maintains | Buy → Buy | — | $10.76 | $10.40 | -3.3% | -4.6% | -3.6% | -2.6% | +8.8% | +1.5% |
| Jan 16 | Needham | Maintains | Buy → Buy | — | $11.16 | $10.93 | -2.1% | -3.6% | -4.6% | -3.6% | -2.6% | +8.8% |
| Nov 13 | JP Morgan | Maintains | Neutral → Neutral | — | $5.46 | $5.36 | -1.8% | +6.8% | +10.8% | +11.1% | -7.1% | +5.7% |
| Nov 9 | Needham | Maintains | Buy → Buy | — | $5.63 | $5.87 | +4.3% | -7.1% | +4.4% | +6.8% | +10.8% | +11.1% |
| Sep 5 | Needham | Maintains | Buy → Buy | — | $9.12 | $9.07 | -0.5% | -4.6% | +4.0% | -7.6% | -3.6% | +3.3% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $11.55 | $11.60 | +0.4% | -5.0% | -9.0% | -4.1% | -2.6% | -1.4% |
| Jul 21 | Needham | Maintains | Buy → Buy | — | $14.81 | $15.30 | +3.3% | +4.5% | -7.7% | +2.7% | -7.0% | -5.3% |
| Jul 18 | Needham | Maintains | Buy → Buy | — | $13.40 | $13.84 | +3.2% | +1.7% | +16.4% | -6.6% | +4.5% | -7.7% |
| Jul 13 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $12.08 | $11.98 | -0.8% | +2.9% | -4.3% | +12.6% | +1.7% | +16.4% |
| Jul 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.08 | $11.98 | -0.8% | +2.9% | -4.3% | +12.6% | +1.7% | +16.4% |
| Jul 12 | Needham | Maintains | Buy → Buy | — | $6.78 | $14.67 | +116.4% | +78.2% | +2.9% | -4.3% | +12.6% | +1.7% |
| Jul 12 | Berenberg | Maintains | Buy → Buy | — | $6.78 | $14.67 | +116.4% | +78.2% | +2.9% | -4.3% | +12.6% | +1.7% |
| May 9 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $5.60 | $5.54 | -1.1% | +2.9% | -4.3% | -2.0% | -2.0% | +5.9% |
| Jan 23 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $8.65 | $8.55 | -1.2% | +0.7% | -1.4% | -4.3% | -0.4% | +4.3% |
| Nov 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $9.60 | $9.76 | +1.7% | +6.7% | +8.5% | +12.3% | +1.8% | -6.6% |
| Oct 25 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $10.91 | $10.97 | +0.6% | -1.7% | +2.1% | -3.3% | +4.7% | -4.9% |
| Aug 11 | Goldman Sachs | Maintains | Neutral → Neutral | — | $9.87 | $9.90 | +0.3% | +13.6% | +7.4% | +7.6% | -4.9% | -6.5% |
| May 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $5.80 | $5.44 | -6.1% | -6.0% | +0.7% | +4.2% | +7.9% | -0.8% |
| May 12 | Goldman Sachs | Maintains | Neutral → Neutral | — | $5.04 | $4.92 | -2.4% | +3.4% | +8.3% | +0.5% | +7.8% | -8.0% |
| Apr 18 | BofA Securities | Downgrade | Buy → Neutral | — | $7.46 | $6.91 | -7.4% | -12.5% | -0.8% | -0.8% | -4.5% | -2.3% |
| Mar 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.91 | $6.82 | -1.3% | +0.4% | -2.6% | +1.6% | +6.6% | -2.6% |
| Mar 4 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $9.70 | $9.22 | -4.9% | -21.1% | -7.3% | +0.4% | +8.1% | -5.1% |
| Dec 8 | SVB Leerink | Maintains | Outperform → Outperform | — | $20.72 | $20.11 | -3.0% | -4.4% | -4.9% | +0.7% | +2.4% | -4.2% |
| Aug 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $22.47 | $22.73 | +1.2% | -8.8% | -2.9% | -4.4% | +0.6% | +3.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | Borgeson BlakeDir | — | Sell | 30,000 | $3.52 | $106K | 6,199,863 | +1.53% | — |
8-K · 2.02
!! High
Recursion Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Recursion Pharmaceuticals reported Q1 2026 financial results, with the company announcing operational performance metrics and financial condition updates to investors on May 6, 2026.
May 6
8-K · 5.02
!!! Very High
Recursion Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Recursion Pharmaceuticals appoints Christopher Gibson as director while he simultaneously declines re-election, suggesting a transitional leadership change with unclear long-term implications.
Apr 30
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
RXRX's chief financial officer departure effective April 6, 2026 creates near-term leadership uncertainty and potential operational disruption during what may be a critical business phase.
Mar 25
8-K · 7.01
! Medium
Recursion Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Recursion Pharmaceuticals shared investor presentation materials from its February 25, 2026 earnings call, providing stakeholders updated company guidance and operational updates through publicly disclosed disclosure.
Feb 25
Data updated apr 26, 2026 11:49pm
· Source: massive.com